| Literature DB >> 22364187 |
Lu Zhang1, Qingzhong Wang, Wenjie Wang, Yanyan Liu, Jie Wang, Jun Yue, Ying Xu, Wenxi Xu, Zhenling Cui, Xuelian Zhang, Honghai Wang.
Abstract
BACKGROUND: Early diagnosis and treatment of Mycobacterium tuberculosis infection can prevent most deaths resulting from this pathogen; however, multidrug-resistant strains present serious threats to global tuberculosis control and prevention efforts. In this study, we identified antigens that could be used for the serodiagnosis of drug-resistant M. tuberculosis strains, using a proteomics-based analysis.Entities:
Year: 2012 PMID: 22364187 PMCID: PMC3305424 DOI: 10.1186/1477-5956-10-12
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1Comparison of 2-DE analysis and western blot analysis of different . 80 μg of total protein lysates from M. tuberculosis were loaded in the first dimension and approximately 1000 spots were detected after silver staining. Proteins identified were indicated by spot number and in Table 1. (A) 2-DE analysis of cell lysates from antibiotic-susceptible strains (a1), multi-drug resistant strains (a2). (B) Western blot analysis of 2-DE maps of M. tuberculosis using pooled serum from patients infected with MDR clinical strains. Protein lysates examined were from sensitive (b1), multi-drug resistant strains (b2). (C) Western blot analysis of 2-DE maps of M. tuberculosis using pooled serum from patients infected with antibiotic-sensitive clinical strains. Protein lysates were from sensitive (c1), multi-drug resistant strains (c2). Gels were electroblotted onto PVDF membranes using a semidry transfer unit. All seras were used at the same dilution to 1:400. Labeled protein spots were excised from corresponding 2DE reference gels run in parallel and subsequently identified using MALDI-TOF-MS and MALDI-TOF-MS/MS analysis.
Immunoreactive protein spots identified by MALDI-TOF-MS
| NCBI accession no.b | Protein identification | MW/PI | Mascot scorec | GRAVY scored | 2D immunoreactivity | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Theoretical | Experimental | Sensitive | RIFr | MDR | ||||||
| M1 | gi|1322434 | ATP synthase beta chain (atpD) | 53093.32/4.76 | 53061.2/4.86 | 433, 57 | -0.168 | S-serae | All sera | All sera | |
| M2 | gi|2916918 | Acyl-CoA thiolase (fadA) | 42413.60/5.14 | 42387.8/5.2 | 181, 32 | 0.035 | R-sera | -- | -- | |
| M3 | gi|15610828 | Methanol dehydrogenase regulatory protein(moxR2) | 37903.47/5.51 | 37904.3/5.43 | 192, 20 | -0.002 | -- | R-sera | -- | |
| M4 | gi|15610165 | electron transfer flavoprotein (alpha subunit) (fixB, etfA) | 31690.02/4.61 | 31699.8/4.47 | 746, 68 | 0.358 | -- | -- | R-sera | |
| M5 | gi|2791638 | Conserved hypothetical protein | 31484.26/4.50 | 31465.7/4.65 | 98, 6 | -0.297 | -- | -- | R-sera | |
| M6 | gi|2104333 | antigen 84(wag31) | 28276.23/4.75 | 28260.1/4.80 | 133, 49 | -0.726 | -- | -- | R-sera | |
| M7 | gi|15607779 | Transcription antitermination protein(nusG) | 25413.54/4.59 | 25431.0/4.70 | 175, 23 | -0.180 | -- | -- | R-sera | |
| M8 | gi|15607585 | Conserved hypothetical protein | 23882.15/5.82 | 23883.0/5.81 | 75, 13 | 0.062 | -- | R-sera | -- | |
| S1 | gi|2896768 | Heat Shock Protein hspX (14-kDa antigen) | 16226.30/4.90 | 16217.2/5.0 | 209, 35 | -0.52 | -- | S-sera | -- | |
a) Spot numbers refer to the numbers on the 2-DE gels showed in Figure 1A-C.
b) Accession no. obtained from the MASCOT results of MALDI-TOF/TOF from the NCBInr database http://www.ncbi.nlm.nih.gov.
c) MASCOT score and percent sequence coverage of all tryptic peptides identified by MALDI-TOF-MS/MS. MASCOT protein scores (based on combined MS and MS/MS spectra (Additional files 1, 2, 3, 4, 5, 6, 7 and 8) greater than 72 were considered statistically significant (p ≤ 0.05).
d) Grand average of hydropathy.
e) Anti-sera from TB patients infected with antibiotic-sensitive M. tuberculosis.
f) Anti-sera from TB patients infected with drug-resistant M. tuberculosis
Figure 2SDS-PAGE analysis of recombinant proteins. Rv0859c, Rv2031c, Rv2145c, Rv3692, Rv0444c and Rv3040 were subjected to SDS-PAGE and stained with Coomassie blue. Molecular size markers are indicated on the left in kDa.
Figure 3Subcellular localization of . Lysates from M. tuberculosis H37Rv were fractionated into cytosol (CY), cell membrane (CM), cell wall (CW) and culture filtrate (CF) fractions. These fractions were normalized for total protein content (50 μg) before SDS-PAGE and then electroblotted onto a PVDF membrane and probed with rabbit-antisera raised against Rv0859c, Rv2031c, Rv2145c, Rv3692, or Rv0444c, respectively.
Figure 4TB serodiagnose for clinical samples applied with different proteins. HC, healthy Mycobacterium bovis BCG-vaccinated controls; S-TB, pulmonary tuberculosis patients infected by antibiotic-sensitive M. tuberculosis strains; M-TB, pulmonary tuberculosis patients infected by multi-drug resistant M. tuberculosis strains.Serum reactivity to (A) Rv2031c and Rv3692 at a 1:1 ratio, (B) Rv2031c and Rv3692 at a 2:1 ratio (C) Rv2031c and Rv3692 at a 3:1 ratio and (D) Rv2031c, Rv3692, and Rv0444c at a 1:1:1 ratio.
IgG seroreactivity to recombinant M. tuberculosis proteins
| Recombination proteins | MDRa | Susceptibleb | Healthy controls | |
|---|---|---|---|---|
| Total/Pos(%) | Total/Pos(%) | Total/Pos(%) | ||
| Rv0859c | 60/14(23.3) | 20/1(5) | 20/0(0) | |
| Rv2031c | 60/20(33.3) | 20/2(10) | 20/0(0) | |
| Rv2145c | 60/13(21.7) | 20/0(0) | 20/0(0) | |
| Rv3692 | 60/22(37) | 20/0(0) | 20/1(5) | |
| Rv0444c | 60/15(25) | 20/3(15) | 20/0(0) | |
| Rv3040 | 60/7(11.7) | 20/2(10) | 20/3(15) | |
| Rv2031c: | 1:1 | 60/33(55) | 20/5(25) | 20/0(0) |
| Rv3692 | 2:1 | 60/34(56.7) | 20/10(50) | 20/0(0) |
| 3:1 | 60/21(35) | 20/7(35) | 20/1(5) | |
| Rv2031c:Rv3692: | 60/34(56.7) | 20/9(45) | 20/0(0) | |
| Rv0444c(1:1:1) | ||||
a) Serum from multi drug-resistant M. tuberculosis infected patients.
b) Serum from antibiotic-susceptible M. tuberculosis infected patients.
Primers sets for genes amplified by PCR
| Gene | Primer sequences(5'-3') | Restriction site used |
|---|---|---|
| 5' C | EcorI | |
| 5' TAT | HinD III | |
| 5' TA | BamHI | |
| 5' TAT | HinD III | |
| 5' TA | BamHI | |
| 5' TAT | HinD III | |
| 5' TA | BamHI | |
| 5' TA | SacI | |
| 5' TA | BamHI | |
| 5' GAC | HinD III | |
| 5' TA | BamHI | |
| 5' TGT | HinD III | |
| 5' T | BamHI | |
| 5' TAT | HinD III | |
| 5' TA | BamHI | |
| 5' GCG | HinD III | |
| 5' AT | BamHI | |
| 5' TAT | HinD III |